Stemcell, 72532, Imatinib

Imatinib mesylate is a first generation tyrosine kinase inhibitor that selectively targets certain tyrosine kinases, including ABL, platelet-derived growth factor receptor (PDGFR), and KIT (Druker, 2008; Müller).

DIFFERENTIATION

· Inhibits proliferation of primary cultured human mesenchymal stem cells, and promotes adipogenic over osteogenic differentiation (Fierro et al.).

· Induces osteoblast differentiation in cultured osteoblastic cells, and reduces osteoclastogenesis in mouse bone marrow cultures (O’Sullivan et al.).

CANCER RESEARCH

· In CML, Imatinib inhibits the oncoprotein BCR-ABL, the product of the Philadelphia chromosome gene fusion (Carroll et al.; Druker et al., 1996).

· Inhibits autonomous erythropoiesis in peripheral blood mononuclear cells isolated from patients with polycythemia vera (Oehler et al.).